HASBROUCK HEIGHTS, N.J., March 19, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NYMX) is pleased to announce that Mark Staples PhD has joined Nymox as Vice President for Chemistry, Manufacturing, and Controls (CMC). Dr Staples is an expert in the field of biopharmaceutical CMC and will be Nymox's VP in charge of these activities.
During his career Dr Staples has led innovative pharmaceutical development teams, supervised successful CMC modules of regulatory filings for drugs and biologics, managed technology transfer to production facilities, and functioned in upper management in a variety of senior positions. Dr Staples held senior positions with highly successful biopharmaceutical companies such as Biogen and other well-known corporations. He has extensive business knowledge and experience in manufacturing, project management, and regulatory matters in the biopharmaceutical sector. Marquis Who's Who, presented Dr Staples with the Albert Nelson Marquis Lifetime Achievement Award in 2018. Dr Staples earned his PhD in Chemistry from the University of Kansas, and did post-doctoral work at Harvard Medical School.
Dr Paul Averback, CEO of Nymox, said, "The Nymox Board and Management are pleased to welcome Dr Staples to the team as VP heading our chemistry, manufacturing and control (CMC) activities. Mark is a distinguished expert in the field and has managed many major projects in his career, including CMC modules of highly important drug approvals. Dr Staples held senior CMC positions for many years at Biogen and other well-known companies, and he has an enviable record of well-known major project successes. Mark's depth of knowledge and experience with all aspects of the business will bring considerable added value to the activities of Nymox and will greatly benefit and strengthen our organization."
Nymox recently announced the publication of an important peer review article entitled "Efficacy and Safety of Fexapotide Triflutate in Outpatient Medical Treatment of Male Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia", authored by Neal Shore MD, Ronald Tutrone MD, and Claus Roehrborn MD, in Therapeutic Advances in Urology 219, 11, 1-16. The report reviews Fexapotide Triflutate which is Nymox's first-in-class new molecular approach to managing BPH symptoms.
According to the article, “For many men suffering from BPH, there remains an unmet need for office- based treatments for BPH that are effective and that have fewer side effects and better safety profiles than existing approved molecular and surgical treatments. Large long-term prospective randomized US studies of FT have shown statistically significant long-term improvement in BPH symptoms and objective outcomes including significant reduction in both spontaneous acute urinary retention as well as the subsequent incidence of BPH surgery. Based on a total of >1700 patient treatments including FT and placebo in US trials to date since 2002, FT has been shown to be well tolerated with an excellent safety profile. FT is a well-tolerated and efficacious clinic-based treatment for BPH involving an intraprostatic injection that requires only a few minutes to administer, with no catheter nor anesthesia requirements. FT injection represents a novel, first-in-class BPH treatment modality”.
The Company will host a shareholder teleconference on March 25 to update current progress in business and regulatory submission activities.
For more information please contact email@example.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2017, and its Quarterly Reports.
For Further Information Contact:
Nymox Pharmaceutical Corporation